-

ABIONYX Pharma Announces Its Financial Calendar for the Year 2026

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News:

ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announces its financial calendar for 2026.

Events

Dates*

Cash position and activity update for Q4 2025

Thursday, February 26, 2026

2025 Full-Year Results

Thursday, March 12, 2026

Cash position and activity update for Q1 2026

Thursday, May 28, 2026

Cash position and activity update for Q2 2026

Thursday, August 27, 2026

2026 Half-Year Results

Thursday, September 24, 2026

Cash position and activity update for Q3 2026

Thursday, November 26, 2026

* indicative dates subject to change

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through breakthrough biotherapies that address life-threatening conditions with no effective treatments. Leveraging its proprietary apoA-I–based technology platform, ABIONYX Pharma develops innovative biologics and HDL-derived vectors that target the immune and inflammatory dysregulation underlying sepsis and other severe diseases. With a strong scientific foundation and a growing network of global clinical partners, ABIONYX Pharma aims to redefine the standard of care in sepsis and to bring critical care solutions to patients worldwide.

Contacts

ABIONYX Pharma
infos@abionyx.com

ABIONYX Pharma

BOURSE:ABNX
Release Versions
EnglishFrench

Contacts

ABIONYX Pharma
infos@abionyx.com

More News From ABIONYX Pharma

ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract with TP ICAP (Europe) SA

TOULOUSE, France--(BUSINESS WIRE)--Regulatory News: Under the liquidity contract covering ABIONYX Pharma shares (FR0012616852 – ABNX FP) entrusted to TP ICAP (Europe), the following assets were included in the liquidity account on December 31, 2025: Number of shares: 63,024 Cash balance: 250,951.67 € During the 2nd half of 2025, a total of : PURCHASE 437,203 shares 1,389,323.53 € 369 transactions SALE 536,477 shares 1,560,333.66 € 502 transactions As a reminder, at the half-yearly balance sheet...

ABIONYX Pharma Carries Out a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today carries out a capital increase with the removal of preferential subscription rights (“PSR”) for certain categories of persons, for an amount of nearly 1.8 million euros through the issuance of 580,643 new sha...

ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announces the launch of a capital increase with the removal of preferential subscription rights (“PSR”) for certain categories of persons, for an amount of nearly 1.8 million euros through the issuance of 580...
Back to Newsroom